TCT 366: Hyperoxemic Supersaturated Oxygen Therapy in Patients With Acute Anterior Myocardial Infarction Reduces Infarct Size and Microvascular Obstruction – a Cardiac Magnet Resonance Imaging Analysis
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker’s Bureau - Abiomed; Amgen; AstraZenca; Daiichi-Sankyo/Elil Lilly and Company; Boehringer Ingelheim; Bayer AG; Berlin Chemie; Bristol-Myers Squibb; Pfizer; Zoll
- Grant Support/Research Contract - Abiomed; Daiichi-Sankyo/Elil Lilly and Company